119 related articles for article (PubMed ID: 20508904)
1. Investigating clearance mechanisms for recombinant activated factor VII in a perfused liver model.
Appa R; Theill C; Hansen L; Møss J; Behrens C; Nicolaisen EM; Klausen NK; Christensen MS
Thromb Haemost; 2010 Aug; 104(2):243-51. PubMed ID: 20508904
[TBL] [Abstract][Full Text] [Related]
2. The unsialylated subpopulation of recombinant activated factor VII binds to the asialo-glycoprotein receptor (ASGPR) on primary rat hepatocytes.
Seested T; Nielsen HM; Christensen EI; Appa RS
Thromb Haemost; 2010 Dec; 104(6):1166-73. PubMed ID: 20886190
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
Morfini M; Bjerre J
Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
[TBL] [Abstract][Full Text] [Related]
4. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs.
Agersø H; Kristensen NR; Østergaard H; Karpf DM; Hermit MB; Pelzer H; Petersen LC; Ezban M
Eur J Pharm Sci; 2011 Apr; 42(5):578-83. PubMed ID: 21382491
[TBL] [Abstract][Full Text] [Related]
5. In vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver.
Seested T; Appa RS; Christensen EI; Ioannou YA; Krogh TN; Karpf DM; Nielsen HM
Thromb Res; 2011 Apr; 127(4):356-62. PubMed ID: 21262526
[TBL] [Abstract][Full Text] [Related]
6. Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans.
Schut AM; Hyseni A; Adelmeijer J; Meijers JC; De Groot PG; Lisman T
Thromb Haemost; 2014 Aug; 112(2):304-10. PubMed ID: 24695949
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
Agersø H; Tranholm M
Haemophilia; 2012 Jul; 18 Suppl 5():6-10. PubMed ID: 22757678
[TBL] [Abstract][Full Text] [Related]
8. Clearance of rat C-reactive protein in vivo and by perfused liver.
Yang C; Mookerjea S; Nagpurkar A
Glycobiology; 1992 Feb; 2(1):41-8. PubMed ID: 1550988
[TBL] [Abstract][Full Text] [Related]
9. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).
Gopalakrishnan R; Hedner U; Ghosh S; Nayak RC; Allen TC; Pendurthi UR; Rao LV
J Thromb Haemost; 2010 Feb; 8(2):301-10. PubMed ID: 19943873
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of using recombinant factor VIIa in continuous infusion.
Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
[TBL] [Abstract][Full Text] [Related]
11. alpha3-galactosylated glycoproteins can bind to the hepatic asialoglycoprotein receptor.
Joziasse DH; Lee RT; Lee YC; Biessen EA; Schiphorst WE; Koeleman CA; van den Eijnden DH
Eur J Biochem; 2000 Nov; 267(21):6501-8. PubMed ID: 11029595
[TBL] [Abstract][Full Text] [Related]
12. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma.
Johansen PB; Bjørn SE; Agersø H; Thorup I; Hermit MB; Sørensen B; Stennicke HR; Ezban M; Tranholm M
Thromb Haemost; 2010 Jul; 104(1):157-64. PubMed ID: 20390231
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of two different recombinant activated factor VII formulations.
Morfini M; Jiménez-Yuste V; Eichler H; Fischer R; Kirchmaier CM; Scharling B; Bjerre J
Haemophilia; 2012 May; 18(3):431-6. PubMed ID: 21999231
[TBL] [Abstract][Full Text] [Related]
14. The kidneys play an important role in the clearance of rFVIIa in rats.
Vestergaard B; Appa RS; Lykkesfeldt J; Agersø H
Thromb Res; 2014 Jun; 133(6):1124-9. PubMed ID: 24731563
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.
Villar A; Aronis S; Morfini M; Santagostino E; Auerswald G; Thomsen HF; Erhardtsen E; Giangrande PL
Haemophilia; 2004 Jul; 10(4):352-9. PubMed ID: 15230949
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of the recombinant factor VIIa in rat bone: importance of the Gla-domain and relevance to factor IX, another vitamin K-dependent clotting factor.
Thomsen MK; Wildgoose P; Nilsson P; Hedner U
Pharmacol Toxicol; 1993 Sep; 73(3):127-32. PubMed ID: 7903449
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte clearance and pharmacokinetics of recombinant factor IX glycosylation variants.
Blasko E; Brooks AR; Ho E; Wu JM; Zhao XY; Subramanyam B
Biochem Biophys Res Commun; 2013 Nov; 440(4):485-9. PubMed ID: 24036269
[TBL] [Abstract][Full Text] [Related]
18. Asparagine-linked oligosaccharide structures determine clearance and organ distribution of pituitary and recombinant thyrotropin.
Szkudlinski MW; Thotakura NR; Tropea JE; Grossmann M; Weintraub BD
Endocrinology; 1995 Aug; 136(8):3325-30. PubMed ID: 7628367
[TBL] [Abstract][Full Text] [Related]
19. Prolonged in-vivo half-life of factor VIIa by fusion to albumin.
Weimer T; Wormsbächer W; Kronthaler U; Lang W; Liebing U; Schulte S
Thromb Haemost; 2008 Apr; 99(4):659-67. PubMed ID: 18392323
[TBL] [Abstract][Full Text] [Related]
20. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.
Mathijssen NC; Masereeuw R; Holme PA; van Kraaij MG; Laros-van Gorkom BA; Peyvandi F; van Heerde WL
Thromb Res; 2013 Aug; 132(2):256-62. PubMed ID: 23834817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
